Allison DeAngelis from STAT News - Journalist Profile

	Profile	Recent Articles on Subject
1	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	The pharma industry’s silence on RFK Jr., and efforts by parents to develop gene therapies for their children - 8 days ago STAT+: Young biotech venture firm raises $500 million for its second fund - 11 days ago STAT+: ‘Significant talent shortage’ threatens the rise of radiopharmaceuticals - 19 days ago STAT+: Recursion, the AI drug development company, cuts more jobs after finalizing Exscientia merger - 24 days ago Pfizer’s new R&D head, a VC deep-dive, and a new FDA commissioner? - 29 days ago STAT+: Former NCI chief and serial biotech entrepreneur raise $70 million to start companies that fail fast - about 1 month ago STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - about 1 month ago Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - about 2 months ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - about 2 months ago STAT+: Seaport Therapeutics adds another $225 million to coffers to embrace the ‘golden age of neuroscience’ - 2 months ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 2 months ago Biotech veteran Tony Coles on partisan politics and fulfilling a promise to his co-founder - 2 months ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - 3 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 3 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 4 months ago STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target - 4 months ago STAT+: Novartis to spend $200 million in further bid to boost radiopharma manufacturing, market dominance - 4 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 4 months ago STAT+: Tome Biosciences, once a high-flying gene-editing startup, is floundering - 4 months ago STAT+: AI drug firm Recursion seeks to move from survival to industry domination - 4 months ago Listen: Drug pricing drops & psychedelics under fire - 4 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 5 months ago STAT+: Biotech led by J&J veterans launches with $165 million for cancer, autoimmune therapies - 5 months ago STAT+: Cardiovascular startup raises $260 million led by ex-Moderna execs’ new VC fund - 5 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 5 months ago STAT+: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical - 7 months ago Listen: More tumult at BIO & coercive care for sickle cell patients - 7 months ago Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama - 8 months ago Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - 8 months ago STAT+: Biotech startups post strongest financing numbers in two years - 9 months ago Listen: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise - 9 months ago STAT+: Investors funnel $275 million into Paragon Therapeutics spinout - 9 months ago STAT+: As AI proliferates, biopharma companies seek to harness it in clinical trials - 9 months ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - 9 months ago STAT+: How biotech investors spot opportunity when stocks are down — and up - 9 months ago Listen: Live! From the STAT Breakthrough Summit East - 9 months ago STAT+: Immuno-oncology startup launches with $150 million, ex-Surface, Bluebird exec as CEO - 9 months ago STAT+: Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline - 9 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 9 months ago Listen: VC turmoil, GLP-1 competition, & the war on recovery - 10 months ago STAT+: Biotech FogPharma raises $145 million in anticipation of more clinical trials, pharma partnerships - 10 months ago Listen: Legal insider trading, booming biotech stocks, & the next GLP-1 - 10 months ago STAT+: Biotech launches with $82 million for Parkinson’s cell therapy - 10 months ago Q&A: A biotech VC leader shares her next big bets - 10 months ago Humira’s legacy, CEO symbolism, and genomic surgery - 10 months ago STAT+: Flagship Pioneering startup lays off a third of staff - 10 months ago Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking - 10 months ago STAT+: Biotech launches with $135 million for Vertex-competing pain medicine - 10 months ago STAT+: Startup BioAge raises $170 million Series D for Zepbound combination therapy - 10 months ago Listen: AI in medicine, detangling hype, and Icelandic DNA - 11 months ago
2	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	The pharma industry’s silence on RFK Jr., and efforts by parents to develop gene therapies for their children - 8 days ago Pfizer’s new R&D head, a VC deep-dive, and a new FDA commissioner? - 29 days ago Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - about 2 months ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - about 2 months ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 2 months ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - 3 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 3 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 4 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 4 months ago Listen: Drug pricing drops & psychedelics under fire - 4 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 5 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 5 months ago Listen: More tumult at BIO & coercive care for sickle cell patients - 7 months ago Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama - 8 months ago Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - 8 months ago Listen: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise - 9 months ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - 9 months ago Listen: Live! From the STAT Breakthrough Summit East - 9 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 9 months ago Listen: VC turmoil, GLP-1 competition, & the war on recovery - 10 months ago Listen: Legal insider trading, booming biotech stocks, & the next GLP-1 - 10 months ago Humira’s legacy, CEO symbolism, and genomic surgery - 10 months ago Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking - 10 months ago Listen: AI in medicine, detangling hype, and Icelandic DNA - 11 months ago
3	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	The pharma industry’s silence on RFK Jr., and efforts by parents to develop gene therapies for their children - 8 days ago Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - about 2 months ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - about 2 months ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 2 months ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - 3 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 3 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 4 months ago STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target - 4 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 4 months ago Listen: Drug pricing drops & psychedelics under fire - 4 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 5 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 5 months ago
4	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Former NCI chief and serial biotech entrepreneur raise $70 million to start companies that fail fast - about 1 month ago STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - about 1 month ago
5	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - about 1 month ago STAT+: Tome Biosciences, once a high-flying gene-editing startup, is floundering - 4 months ago
6	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - about 1 month ago
7	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry - about 1 month ago
8	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - 8 months ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - 9 months ago Listen: Live! From the STAT Breakthrough Summit East - 9 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 9 months ago Listen: VC turmoil, GLP-1 competition, & the war on recovery - 10 months ago Listen: Legal insider trading, booming biotech stocks, & the next GLP-1 - 10 months ago Humira’s legacy, CEO symbolism, and genomic surgery - 10 months ago Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking - 10 months ago Listen: AI in medicine, detangling hype, and Icelandic DNA - 11 months ago
9	Mario Aguilar STAT News Reporter at STATnews. Previous engagements noted. Personal views. Brooklyn techhealth care	STAT+: How biotech investors spot opportunity when stocks are down — and up - 9 months ago